IJPSR (2026), Volume 17, Issue 4 **(Research Article)**

INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH

Received on 17 October 2025; received in revised form, 06 December 2025; accepted, 17 December 2025; published 01 April 2026

POPULATION-BASED BIOINFORMATIC CHARACTERIZATION OF VKORC1 GENE VARIANTS INFLUENCING WARFARIN SENSITIVITY-A DESCRIPTIVE STUDY

C. N. Ramya Murthy [1] and K. G. Satheesh Kumar [* 2]

Department of Pharmacology [1], Kurnool Medical College, Kurnool - 518002, Andhra Pradesh, India.
Department of Pharmacology [2], Sri Venkateshwara Medical College, Tirupati - 517507, Andhra Pradesh, India.

Keywords:

VKORC1 polymorphisms, Warfarin sensitivity, Pharmacogenomics, Population genetics, *In-silico* analysis

Correspondence to Author:
Dr. K. G. Satheesh Kumar

Final Year Postgraduate,
Department of Pharmacology,
Sri Venkateshwara Medical College,
Tirupati - 517507, Andhra Pradesh,
India.

E-mail: satsan244@gmail.com

ABSTRACT: Background: Warfarin dosing varies greatly between individuals and across populations, and much of this variation is driven by polymorphisms in the *VKORC1* gene. Understanding how these variants influence gene expression and function is crucial for improving dose accuracy and preventing complications. **Objective:** To characterise key *VKORC1* variants using an *in-silico* approach and to assess how their predicted functional effects and population frequencies contribute to global differences in warfarin sensitivity. **Methods:** Genomic data from gnomAD and the 1000 Genomes Project were analysed to examine major *VKORC1* variants across South Asian, European, and East Asian populations. Functional and regulatory impacts were predicted using SIFT, PolyPhen-2, PROVEAN, ConSurf, JASPAR, and RegulomeDB. Genotype frequencies were estimated using the Hardy–Weinberg model and interpreted in relation to expected warfarin dosing categories, including sensitive, intermediate, and normal-dose groups. **Results:** The promoter variant rs9923231 and intronic variant rs9934438, both linked to reduced *VKORC1* expression and lower warfarin dose requirements, were most frequent in East Asians (around 80–90%). The 3′UTR variant rs7294, associated with higher gene activity and increased dose needs, was predominantly seen in South Asians (~69%). The rare coding variant rs61742245 (Asp36Tyr), predicted to cause major structural disruption and warfarin resistance, occurred at less than 0.1%. Overall, East Asians showed more sensitivity-linked genotypes, Europeans displayed mixed patterns, and South Asians carried more resistance-associated variants. **Conclusion:** *VKORC1* variability significantly shapes inter-ethnic warfarin dose differences. Incorporating these variants into population-tailored dosing strategies may improve the safety and precision of anticoagulation therapy.

INTRODUCTION: Warfarin remains a widely used anticoagulant for preventing and treating thromboembolic disorders, yet its clinical use is complicated by a narrow therapeutic window and marked inter-individual dose variability [1]. The enzyme encoded by the *VKORC1* gene (vitamin K epoxide reductase complex subunit 1) is the pharmacologic target of warfarin, and genetic variation within this gene has been shown to significantly influence sensitivity to warfarin, thereby altering both dose requirement and bleeding risk [2, 3].

In diverse ethnic groups including Middle Eastern, South Asian and Latin American cohorts studies have demonstrated that common polymorphisms of *VKORC1* (such as -1639G>A or rs9923231) are strongly associated with reduced warfarin dose requirement, thereby contributing to dose variability at a population level [4, 5, 6]. However, the functional impact of many *VKORC1* variants

QUICK RESPONSE CODE

DOI: 10.13040/IJPSR.0975-8232.17(4).1226-33

This article can be accessed online on www.ijpsr.com

DOI link: https://doi.org/10.13040/IJPSR.0975-8232.17(4).1226-33

particularly rare, regulatory, or population-specific alleles remains poorly characterised. Most previous research has focused on a small set of common polymorphisms, leaving important gaps in understanding how diverse *VKORC1* sequence changes may affect gene regulation, protein structure, and ultimately, warfarin sensitivity.

Bioinformatic approaches offer a practical and scalable way to address these gaps. *In-silico* tools allow researchers to explore evolutionary conservation, structural changes, and regulatory effects, giving early indications of how a variant might influence *VKORC1* function even before clinical studies are performed [7]. However, only a limited number of investigations have combined these functional predictions with population-level allele frequency data, which is essential for understanding global differences in warfarin response. This study therefore conducts a systematic *in-silico* characterisation of both common and rare *VKORC1* variants across major populations. By linking predicted functional effects with population distributions, the study aims to enhance understanding of *VKORC1*-driven variability in warfarin sensitivity and support more precise, population-tailored dosing strategies.

METHODOLOGY:

Data Sources: Publicly available genomic datasets were used for this *in-silico* analysis. Allele frequency data for *VKORC1* variants were obtained from the Genome Aggregation Database (gnomAD v2.1.1) and the 1000 Genomes Project Phase 3. Three major global populations were evaluated: South Asians (SAS), Europeans (EUR), and East Asians (EAS), selected due to known differences in warfarin response and *VKORC1* variant distribution. As only secondary datasets and computational tools were utilised, no ethical approval was required. Variant Selection: *VKORC1* variants were included if allele frequency data were available in at least one selected population. Functionally relevant promoter, intronic, 3′UTR, regulatory, coding, and intergenic variants commonly implicated in warfarin pharmacogenomics were prioritised. The final panel included: rs9923231 (promoter), rs9934438 (intronic), rs7294 (3′UTR), rs17708472 (regulatory), rs61742245 (missense; Asp36Tyr), rs17878544 (intergenic regulatory).

Functional Prediction Tools: SIFT (v6.2.1), Database: UniProt + Ensembl protein sequences, Output: SIFT score (0–1), Threshold: ≤0.05 = deleterious, >0.05 = tolerated. PolyPhen-2 (version 2.2.2), Models used: HumDiv and HumVar, Output categories: Probably damaging (score >0.85), Possibly damaging (0.15–0.85), Benign (<0.15) PROVEAN (v1.1.5), Database: NCBI NR protein database with BLAST-based clustering, Threshold: ≤ −2.5 = deleterious, > −2.5 = neutral ConSurf (Server v1.0, 2024 release), Algorithm: Bayesian inference using a multiple sequence alignment of homologs, Scoring: 1–9 conservation scale (1 = variable, 9 = highly conserved) JASPAR (2024 Core Vertebrate Database), Approach: Position Frequency Matrix (PFM)–based transcription factor binding site prediction, Output: Predicted gain/loss of TF motifs; relative score threshold ≥80% used for reporting RegulomeDB (v2.0.3), Integrates: ENCODE, ChIP-seq, DNase-seq, ATAC-seq, TF motifs, Score interpretation:1a–1f: likely regulatory with strong evidence, 2a–2c: likely regulatory, 3–6: minimal to no evidence

Genotype counts **Table 4** were estimated using Hardy–Weinberg equilibrium (HWE) with a hypothetical population of n = 1000 for proportional representation of alleles. This approach standardizes comparisons across populations, reflecting relative allele frequencies while enabling visualization of predicted warfarin sensitivity and resistance.

Population Analysis: Allele frequencies for each variant were extracted for SAS, EUR, and EAS populations. Expected genotype frequencies were calculated using Hardy–Weinberg Equilibrium (HWE) proportions (p^2, $2pq$, q^2).

Genotype distributions were mapped to predicted warfarin-response categories: AA = sensitivity / low-dose requirement, AA = intermediate sensitivity, aa = normal-dose phenotype.

Data Processing: All computations and tabulations were performed in Microsoft Excel (Microsoft Office 2021). Functional predictions were manually integrated with population-frequency data to infer variant-level contributions to warfarin dose variability.

Work Flow:



RESULTS:

TABLE 1: STRUCTURAL AND FUNCTIONAL PREDICTION OF *VKORC1* VARIANTS

SNP ID	Nucleotide Change	Genomic Location (GRCh38)	SIFT	PolyPhen-2	Provean	ConSurf Score	Inference
rs9923231	NM_024006.4:c.-1639G>A	16:31096388	N/A	N/A	N/A	N/A	Regulatory variant; reduces *VKORC1* expression.
rs9934438	NM_024006.4:c.1173C>T	16:31096188	N/A	N/A	N/A	N/A	Tag SNP; linked to rs9923231 expression effect.
rs7294	**NM_024006.6:c.134G>A*	16:31090999	N/A	N/A	N/A	N/A	Affects mRNA stability; increases *VKORC1* activity.
rs17708472	NC_000016.10:g.31094032G>A	16:31094032	N/A	N/A	N/A	N/A	Minor regulatory role.
rs61742245	NM_024006.x:c.106G>T	16:31095342	deleterious	probably damaging	deleterious	8–9 (high)	Missense substitution (Asp36Tyr) at a conserved site;

							predicted to impair *VKORC1* structure and cause warfarin resistance.
rs17878544	NC_000016.10:g.31096606T>C	16:31096606	N/A	N/A	N/A	N/A	Neutral variant; no functional effect.

Table 1 shows the structural and functional effects of major *VKORC1* SNPs based on *in-silico* prediction tools. Among all variants, only the missense SNP rs61742245 showed a strong deleterious effect, supported by all protein-prediction tools and high evolutionary conservation, indicating a potential to cause warfarin resistance. The common regulatory variants (rs9923231, rs9934438, rs7294) did not affect protein structure but showed clear transcriptional or post-transcriptional effects.

TABLE 2: REGULATORY VARIANT ANALYSIS OF *VKORC1* PROMOTER AND NONCODING SNPS

SNP ID	Location	Predicted Effect (JASPAR / RegulomeDB)	Functional Consequence
rs9923231	Promoter (−1639 G>A)	Loss of HNF4α E-box motif and gain of GATA2 binding site; high RegulomeDB score indicating strong transcriptional relevance.	Reduces *VKORC1* expression and increases warfarin sensitivity.
rs9934438	Intron 1 (1173 C>T)	Located within enhancer/splicing regulatory region; acts as haplotype tag SNP in strong LD with rs9923231.	Acts as a tag SNP affecting *VKORC1* expression and warfarin dose.
rs7294	3′ UTR (c.*134 G>A)	Predicted to disrupt conserved miRNA binding sites (e.g., miR-133a, miR-137) per JASPAR motif loss; moderate RegulomeDB support.	Influences mRNA stability and interindividual dose variation.
rs17708472	Noncoding transcript region	Weak evidence of enhancer element overlap; no major TF motif predicted.	Possible minor role in transcript regulation; low functional impact.
rs61742245	Coding exon (c.106 G>T; p.Asp36Tyr)	Missense substitution; highly conserved residue predicted deleterious by SIFT/PolyPhen/PROVEAN.	Alters *VKORC1* protein structure and may cause warfarin resistance.
rs17878544	Intergenic region	No significant TF motif or enhancer overlap detected in JASPAR/RegulomeDB.	Likely neutral marker with minimal or no functional effect.

Table 2 shows the predicted transcription factor binding alterations and regulatory consequences of *VKORC1* noncoding SNPs. rs9923231 demonstrated the strongest regulatory influence, with predicted loss of activator binding and reduced *VKORC1* expression, consistent with increased warfarin sensitivity. rs9934438 behaved mainly as a linked marker. rs7294 showed potential disruption of miRNA binding, suggesting higher *VKORC1* expression and reduced sensitivity. Other regulatory variants showed minimal predicted effects.

TABLE 3: ALLELE FREQUENCY OF *VKORC1* VARIANTS ACROSS POPULATIONS

SNP ID	Variant	South Asian (SAS)	European (EUR)	East Asian (EAS)
rs9923231	G>A	17.81%	37.79%	89.17%
rs9934438	C>T	18.62%	37.84%	90.21%
rs7294	G>A	68.77%	37.83%	9.65%
rs17708472	G>A	11.79%	23.26%	0.16%
rs61742245	G>T	0.06%	0.04%	0%
rs17878544	T>,C	0.58%	0.68%	0.03%

Table 3 shows substantial population-level differences in allele frequencies for major *VKORC1* variants. Large interethnic variation was evident. Sensitivity-associated alleles (rs9923231 A, rs9934438 T) were most frequent in East Asians, moderate in Europeans, and least common in South Asians. The resistance-associated rs7294 A allele showed the opposite trend. Rare variants remained uniformly uncommon across populations.

TABLE 4: PREDICTED PHARMACOGENOMIC IMPACT OF *VKORC1* GENOTYPES ON WARFARIN DOSE

SNP ID (Variant)	Population	Genotype Count (AA / Aa / aa)	Functional Effect on *VKORC1*	Warfarin Dose Interpretation	Low Dose/High dose (%) AA	Intermediate (%) Aa	Normal Dose (%) aa
rs9923231 (G>A)	South Asian (SAS)	32 / 293 / 676	A allele decreases *VKORC1* expression	A carriers need reduced dose	3.2 %	29.3 %	67.6 %
	European (EUR)	64 / 320 / 616	A allele decreases *VKORC1* expression	Reduced dose required	6.4 %	32.0 %	61.6 %
	East Asian (EAS)	792 / 195 / 13	A allele decreases *VKORC1* expression	Marked dose reduction	79.2 %	19.5 %	1.3 %
rs9934438 (C>T)	South Asian (SAS)	35 / 303 / 662	T allele decreases *VKORC1* expression	T carriers need reduced dose	3.5 %	30.3 %	66.2 %
	European (EUR)	81 / 360 / 559	T allele decreases *VKORC1* expression	Reduced dose required	8.1 %	36.0 %	55.9 %
	East Asian (EAS)	705 / 265 / 30	T allele decreases *VKORC1* expression	Marked dose reduction	70.5 %	26.5 %	3.0 %
rs7294 (G>A)	South Asian (SAS)	473 / 429 / 98	A allele increases *VKORC1* activity	A carriers need increased dose	47.3 %	42.9 %	9.8 %
	European (EUR)	402 / 448 / 150	A allele increases *VKORC1* activity	A carriers need increased dose	40.2 %	44.8 %	15.0 %
	East Asian (EAS)	290 / 420 / 290	A allele increases *VKORC1* activity	Moderate dose increase	29.0 %	42.0 %	29.0 %
rs17708472 (G>A)	South Asian (SAS)	14 / 208 / 778	A allele decreases *VKORC1* expression	Reduced dose required	1.4 %	20.8 %	77.8 %
	European (EUR)	25 / 200 / 775	A allele decreases *VKORC1* expression	Minor dose reduction	2.5 %	20.0 %	77.5 %
	East Asian (EAS)	90 / 270 / 640	A allele decreases *VKORC1* expression	Moderate dose reduction	9.0 %	27.0 %	64.0 %
rs6174245 (G>T)	South Asian (SAS)	0 / 1 / 999	Rare missense variant – ↓ warfarin binding (resistance)	Higher dose if present	0 %	0.1 %	99.9 %
	European (EUR)	0 / 2 / 998	Same functional effect	Higher dose if present	0 %	0.2 %	99.8 %
	East Asian (EAS)	0 / 0 / 1000	No variant observed	No effect	0 %	0 %	100 %
rs17878544 (T>C)	South Asian (SAS)	0 / 12 / 989	C allele mildly decreases *VKORC1* expression	Mild sensitivity to warfarin	0 %	1.2 %	98.9 %
	European (EUR)	1 / 15 / 984	C allele mildly decreases *VKORC1* expression	Slight dose reduction if carrier	0.1 %	1.5 %	98.4 %
	East Asian (EAS)	0 / 8 / 992	C allele mildly decreases *VKORC1* expression	Negligible effect	0 %	0.8 %	99.2 %

Table 4 shows clear population-level differences in the pharmacogenomic impact of *VKORC1* variants on warfarin dosing. Genotype distributions reflected these frequencies: East Asians showed predominantly sensitivity genotypes, Europeans showed mixed profiles, and South Asians carried more resistance-associated genotypes. Overall, the results reinforce that *VKORC1* regulatory variants especially rs9923231 are key drivers of population-specific warfarin dose requirements.

TABLE 5: SUMMARY OF PHARMACOGENOMIC SIGNIFICANCE OF *VKORC1* VARIANTS

SNP ID	Functional Category	Molecular Effect	Population Distribution Pattern	Effect on *VKORC1* Function	Impact on Warfarin Dose	Clinical Significance
rs9923231	Promoter	Loss of HNF4α	Low in SAS	Decrease in	Decrease	Major determinant of

	regulatory variant	binding; gain of GATA2 site → ↓ transcription	moderate in EUR high in EAS	*VKORC1* expression		warfarin sensitivity; carriers need lower dose
rs9934438	Intron 1 regulatory / haplotype tag SNP	Linked with rs9923231; affects enhancer/splicing regulation	Low in SAS moderate in EUR high in EAS	Decrease in *VKORC1* expression	Decrease	Surrogate marker for dose reduction; clinically validated SNP
rs7294	3′ UTR variant	Alters miRNA (miR-133a/137) binding → ↑ mRNA stability	High in SAS moderate in EUR low in EAS	Increased *VKORC1* translation/activity	Increase	Associated with warfarin resistance; higher dose required
rs17708472	Noncoding regulatory	Weak enhancer overlap, minor TF impact	Moderate in SAS/EUR, rare in EAS	Mild reduction in expression	Decrease (mild)	Minor variant with limited clinical relevance
rs61742245	Coding missense	Deleterious structural change (SIFT/PolyPhen/PROVEAN = deleterious)	Extremely rare (<0.1%)	Alters enzyme conformation → ↓ warfarin binding	Increase	Confers warfarin resistance in carriers
rs17878544	Intergenic / neutral	No functional motif overlap	Very rare (<1%) in all populations	Minimal change	Decrease (negligible)	Likely neutral marker, minor effect on dose requirement

Table 5 shows a consolidated summary of the functional significance of each *VKORC1* variant. Collectively, the results demonstrate that *VKORC1* regulatory variants particularly rs9923231 and rs9934438 drive warfarin sensitivity, whereas rs7294 contributes to resistance, with strong ethnic stratification shaping population-specific dose needs. The *in-silico* findings support the integration of *VKORC1* genotypes in precision dosing frameworks and highlight the importance of population genomics in warfarin therapy.

DISCUSSION: This *in-silico* analysis reinforces that *VKORC1* polymorphisms are key determinants of warfarin dose variability across populations [7, 8]. The promoter variant rs9923231 (−1639G>A) remains the most clinically relevant, with the G→A substitution disrupting HNF4α binding and enhancing GATA2 binding, reducing *VKORC*1 expression and increasing warfarin sensitivity [9]. As expected, East Asians carry this allele at >80%, explaining their lower dose requirements compared to Europeans and South Asians [10].

The intronic variant rs9934438 (1173C>T), which is closely linked to rs9923231, serves as a haplotype tag and indirectly influences *VKORC1* expression through enhancer and splicing mechanisms. European studies have confirmed that individuals with this variant are more sensitive to warfarin [11, 12], supporting its inclusion in CPIC dosing guidelines [13].

In contrast, the rs7294 (3′UTR G>A) variant exerts the opposite pharmacogenomic effect. The substitution of guanine by adenine enhances mRNA stability by altering miRNA binding motifs (such as miR-133a and miR-137), resulting in increased *VKORC1* protein levels and reduced warfarin efficacy. Population-based studies from South and Central Asia demonstrate that the rs7294 A allele reaches frequencies as high as 70% in South Asians and up to 60% in Middle Eastern populations, accounting for their greater average dose requirements [14]. Simulation results from this study also indicated that carriers of the A allele may require up to 20–30% higher warfarin doses to achieve therapeutic INR, consistent with reports from Indian, Pakistani, and Bulgarian cohorts [15].

The rare coding variant rs61742245 (Asp36Tyr), though present in less than 0.1% of individuals globally, disrupts *VKORC1* structure and contributes to warfarin resistance, consistent with clinical observations [8]. Minor variants such as rs17708472 and rs17878544 have limited functional effects but could influence response when occurring alongside high-impact alleles [12]. However, their presence in certain haplotypes suggests a potential modulatory role when combined with high-impact alleles, a hypothesis warranting further molecular investigation. Taken together, these variants show a clear ethnic gradient: East Asians mainly carry sensitivity

alleles, Europeans display intermediate frequencies, and South Asians are enriched for resistance alleles [13, 14]. These patterns emphasize the importance of population-specific *VKORC1* genotyping for personalized anticoagulation, ideally combined with *CYP2C9* and *CYP4F2* genotypes, and point to the potential of machine learning models to further refine individualized warfarin dosing [8, 15]. Understanding this genetic diversity can help achieve safer and more effective therapy across different populations.

Strengths and Limitations: A major strength of this study is its comprehensive integration of multiple bioinformatic tools (SIFT, PolyPhen-2, PROVEAN, ConSurf, JASPAR, and RegulomeDB), enabling a multi-dimensional evaluation of both coding and noncoding *VKORC1* variants. The use of large-scale genomic data from gnomAD and the 1000 Genomes Project provided robust cross-population comparisons.

However, limitations include the absence of clinical validation and reliance on *in-silico* predictions, which may not fully capture the complexity of in-vivo gene regulation and pharmacodynamics. Furthermore, rare variants with uncertain significance warrant functional assays to confirm predicted effects.

CONCLUSION: This study highlights the significant impact of *VKORC1* genetic variants on warfarin response, emphasizing that differences in rs9923231, rs9934438, and rs7294 largely explain inter-individual and inter-ethnic variability in dose requirements. Sensitivity-associated variants, particularly rs9923231 and rs9934438, were most prevalent in East Asians, while rs7294, linked to increased *VKORC1* activity, was common in South Asians, accounting for their higher average dose needs. Rare coding variants such as rs61742245 had strong functional effects but limited population-level influence, and minor variants showed minimal impact. These findings underscore the importance of population-specific genotyping in guiding warfarin dosing. Combining bioinformatic predictions with clinical data can enhance therapeutic safety, reduce adverse events, and support more personalized anticoagulation strategies, advancing precision medicine in pharmacogenomics.

ACKNOWLEDGEMENT: Nil

Funding: Nil

CONFLICT OF INTEREST: Nil

REFERENCES:

1. Holail J, Mobarak R, Al-Ghamdi B, Aljada A and Fakhoury H: Association of VKORC1 and CYP2C9 single-nucleotide polymorphisms with warfarin dose adjustment in Saudi patients. Drug Metab Pers Ther 2022. doi: 10.1515/dmdi-2022-0108. Epub ahead of print. PMID: 35365981
2. Radhi, Ayoob, Aziz and Hussam: The Role of VKORC1 in Vitamin K Metabolism and Warfarin Sensitivity: A Narrative Review of Genetic and Clinical Perspectives. OBAT Jurnal Riset Ilmu Farmasi dan Kesehatan 2025; 3: 287-299. 10.61132/obat.v3i5.1697.
3. Sundari, Ankani, Syamala D & Sivaraj R & G, Somasundaram and Codi R: Impact of cyp2c9 and vkorc1 genetic variants on warfarin therapy optimization in south indian population with venous thromboembolism. Journal of Population Therapeutics and Clinical Pharmacology 2025. 10.53555/2f8rtf51.
4. Fahmi AM, Elewa H and El Jilany I: Warfarin dosing strategies evolution and its progress in the era of precision medicine, a narrative review. International Journal of Clinical Pharmacy 2022; 44.
5. HS: Novel Gene Polymorphisms for Stable Warfarin Dose in a Korean Population: Genome-Wide Association Study. Biomedicines 2023; 11(8): 2308. doi: 10.3390/biomedicines11082308. Erratum in: Biomedicines 2025; 13(5): 1238. doi: 10.3390/biomedicines13051238. PMID: 37626805; PMCID: PMC10452379.
6. Oscanoa TJ, Guevara-Fujita ML, Fujita RM, Muñoz-Paredes MY, Acosta O and Romero-Ortuño R: Association between polymorphisms of the VKORC1 and CYP2C9 genes and warfarin maintenance dose in Peruvian patients. Br J Clin Pharmacol 2024; 90(3): 769-775. doi: 10.1111/bcp.15958. Epub 2023 Nov 24. PMID: 37940132.
7. Bagher AM, Alharbi W, Gadi LS, Binmahfouz LS and Hareeri RH: Allelic Variants in the Warfarin-related Genes VKORC1 and CYP2C9 in a Western Saudi Population. Journal of Pharmacology and Pharmacotherapeutics 2023.
8. Fülöp P, Tóth Š, Porubän T, Fülöpová Z, Borovská A and Dvorožňáková M: Machine Learning for Warfarin Therapy: A Systematic Review. Pharmaceuticals 2025; 18(10): 1544.
9. Tzveova R, Saraeva R, Dimitrova-Karamfilova A, Nachev G, Mitev V and Kaneva R: Establishment of Acenocoumarol Pharmacogenetic Algorithm Including CYP2C9 and VKORC1 Genotypes in Bulgarian Patients Treated with Coumarin Anticoagulants. Acta Medica Bulgarica 2025; 52(2): 12–23.
10. Abouelhoda M, Almuqati N, Abogosh A, Alfraih F, Maddirevula S and Alkuraya FS: Mining local exome and HLA data to characterize pharmacogenetic variants in Saudi Arabia. Human Genetics 2023; 143(2): 125–36.
11. Рени Цвеова, Dimitrova-Karamfilova A, Vandeva S, Atanasov P, Pendicheva-Duhlenska D and Nachev G: Polymorphic variants in acenocoumarol-related genes CYP2C9 and VKORC1 and their frequencies in Bulgarian population. Acta Medica Bulgarica 2025; 52(3): 22–31.
12. Maleki O and Javad Gharechahi: Association of VKORC1 and CYP2C9 gene polymorphisms with warfarin dose

requirements in a representative Iranian population with cardiac valve replacement surgery. Pharmacogenetics and Genomics 2025; 35(7): 214–20.

13. Muyambo S, Ndadza A, Soko ND, Kruger B, Kadzirange G and Chimusa E: Warfarin Pharmacogenomics for Precision Medicine in Real-Life Clinical Practice in Southern Africa: Harnessing 73 Variants in 29 Pharmacogenes. OMICS: a Journal of Integrative Biology 2022; 26(1): 35–50.
14. Khan AR, Shah SH, Ajaz S, Firasat S, Abid A and Raza A: The prevalence of pharmacogenomics variants and their clinical relevance among the Pakistani population. Evolutionary Bioinformatics 2022; 18.
15. Sahana S, Bhoyar RC, Ambily Sivadas, Jain A, Imran M and Rophina M: Pharmacogenomic landscape of Indian population using whole genomes. Clinical and Translational Science 2022; 15(4): 866–77.

How to cite this article:
Murthy CNR and Kumar KGS: "Population-based bioinformatic characterization of vkorc1 gene variants influencing warfarin sensitivity-a descriptive study". Int J Pharm Sci & Res 2026; 17(4): 1226-33. doi: 10.13040/IJPSR.0975-8232.17(4).1226-33.